|

Tagraxofusp-erzs Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, Elzonris, IL3R-targeting Fusion Protein SL-401 +5 more

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • M.D. Anderson Cancer Center1
  • City of Hope Medical Center1

Indications

  • Cancer2
  • Blastic Plasmacytoid Dendritic Cell Neoplasm1
  • Myelodysplastic Syndrome1
  • Acute Myeloid Leukemia1

Duarte, California1 trial

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1

Houston, Texas1 trial

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.